MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Back
enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc. (ENGN)
Income Statement
Quarterly Income Statement for the quarter ending in 2026-07-31
source: myfinsight.com
ENGN Income Statement Sankey Diagram
Sankey diagram visualizing ENGN income statement for the period
Total comprehensive
loss
-$32,711K
(-11.91%↓ Y/Y)
Net loss
-$32,501K
(-12.11%↓ Y/Y)
Unrealized loss (gain) on
available-for-sale investments
-$210K
(12.50%↑ Y/Y)
Interest income
$2,401K
(7.52%↑ Y/Y)
Net loss before
income taxes
-$32,501K
(-13.04%↓ Y/Y)
Total other income,
net
$1,513K
(26.61%↑ Y/Y)
Interest expense
$843K
(11.21%↑ Y/Y)
Other expenses, net
-$45K
(83.93%↑ Y/Y)
Loss from operations
-$34,014K
(-13.58%↓ Y/Y)
Total operating
expenses
$34,014K
(13.58%↑ Y/Y)
Research and development
$20,090K
(-11.01%↓ Y/Y)
General and
administrative
$13,924K
(88.88%↑ Y/Y)
Back